Dose escalation can influence timing because gastrointestinal symptoms may flare around changes
Obesity at diagnosis is linked to a higher risk of recurrence and death in women with hormone receptor-positive disease, particularly those on aromatase inhibitors, and studies also show that gaining more than 10 percent of body weight after diagnosis is associated with worse survival
Semaglutide, a GLP-1 receptor agonist, slows the rate at which your stomach empties its contents into your small intestine by approximately 2030 percent
M2 microglia secrete anti-inflammatory cytokines, such as interleukins-4, -10 and -13 (IL-4, IL-10, and IL-13), transforming growth factor beta-1 (TGF-1), and trophic factors like insulin like growth factor 1 (IGF-1), which help mitigating inflammation and support neuronal survival
GLP-1 medications are part of a medical weight loss strategy that helps regulate appetite, blood sugar, and how the body processes food